Phathom Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Phathom Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-21.3%
Buyback Yield
| Total Shareholder Yield | -21.3% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
Dec 11Following Up On Phathom Pharmaceuticals
Sep 03Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Jun 26Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
Mar 18Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30
Aug 02The Prognosis For Phathom Pharmaceuticals
Jun 22Phathom Pharmaceuticals: Undiscovered Gem
Jan 20Phathom Pharma prices equity offering at $42
Dec 17Phathom Pharma launches equity offering
Dec 15Phantom Pharma completes enrollment in late-stage study of lead candidate in esophagus inflammation disorder
Nov 30Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if PHAT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHAT's dividend payments have been increasing.
Dividend Yield vs Market
| Phathom Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (PHAT) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Pharmaceuticals) | 2.5% |
| Analyst forecast (PHAT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate PHAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PHAT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate PHAT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PHAT has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 22:50 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Phathom Pharmaceuticals, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Umer Raffat | Evercore ISI |